



NDA 18-276/S-034

Pharmacia & Upjohn
Attention: Terry L. Reinstein, R.Ph.
Unit 0635-298-I 13
7000 Portage Road
Kalamazoo, MI 49001-0199

NOV 24 1998

Dear Mr. Reinstein:

Please refer to your supplemental new drug application (S-034) dated August 7, 1997 and received August 11, 1997, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Xanax (alprazolam) Tablets, 0.25, 0.5, 1, and 2 mg.

We also refer to two Agency letters dated January 30 and 31, 1997.

Supplemental application S-034 provides changes to the "Post Introduction Reports" subsection of the ADVERSE REACTIONS section of labeling. These proposed changes are submitted in response to Agency letters dated January 30 and 31, 1997, which request the inclusion of the terms hepatitis, hepatic failure, and Stevens-Johnson syndrome to labeling. Additionally, the supplement provides the inclusion of hyperprolactinemia to this subsection of labeling as a result of articles cited in the medical literature.


Labeling changes of the kind which you have proposed under S-034 are permitted by section 314.70(c) of the regulations to be made prior to approval of the supplement. It is understood that the changes described in S-034 have been implemented.

We have completed the review of this supplemental application and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the final printed labeling (copy code 811 557 826) submitted on August 7, 1997. Accordingly, the supplemental application is approved, effective as of the date of this letter.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions concerning this NDA, please contact Mr. Merrill Mille, R.Ph., Senior Regulatory Management Officer, at (301) 594-5528.

Sincerely yours,

A handwritten signature in black ink, appearing to read "P. Leber", followed by the date "11/23/98". The signature is fluid and cursive.

Paul Leber, M.D.
Director
Division of Neuropharmacological Drug Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research